GSK warns Canadian doctors against Volibris use in IPF
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has sent 'Dear Healthcare Professional' letters in Canada warning against the use of ambrisentan (Volibris) in patients with idiopathic pulmonary fibrosis (IPF), an unlicensed indication.